Methods for developing evidence-based recommendations by the Advisory Committee on Immunization Practices (ACIP) of the U.S. Centers for Disease Control and Prevention (CDC)

被引:75
作者
Ahmed, Faruque [1 ]
Temte, Jonathan L. [2 ]
Campos-Outcalt, Doug [3 ]
Schuenemann, Holger J. [4 ]
机构
[1] Ctr Dis Control & Prevent, Immunizat Serv Div, Atlanta, GA 30333 USA
[2] Univ Wisconsin, Sch Med & Publ Hlth, Dept Family Med, Madison, WI 53715 USA
[3] Univ Arizona, Coll Med, Dept Family & Community Med, Phoenix, AZ 85004 USA
[4] McMaster Univ, Hlth Sci Ctr, Dept Clin Epidemiol & Biostat, Hamilton, ON L8N 3Z5, Canada
关键词
Centers for Disease Control and Prevention; Evidence-based medicine; Evidence-based practice; Immunization Preventive health services; Vaccination; REASSORTANT ROTAVIRUS VACCINE; SERVICES-TASK-FORCE; UNITED-STATES; QUALITY; SAFETY; POLICY; GRADE; GASTROENTERITIS; PROGRAMS; EFFICACY;
D O I
10.1016/j.vaccine.2011.08.005
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The Advisory Committee on Immunization Practices (ACIP) provides expert external advice and guidance to the Director of the Centers for Disease Control and Prevention and the Secretary of the U.S. Department of Health and Human Services on use of vaccines and related agents for control of vaccine-preventable disease in the United States. During the October 2010 ACIP meeting, the ACIP voted to adopt a new framework for developing evidence-based recommendations that is based on the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) approach. Key factors considered in the development of recommendations include the balance of benefits and harms, type of evidence, values and preferences of the people affected, and health economic analyses. Category A recommendations will be made for all persons in an age- or risk-factor-based group. Category B recommendations will be made for individual clinical decision making: category B recommendations do not apply to all members of an age- or risk-factor-based group, but in the context of a clinician-patient interaction, vaccination may be found to be appropriate for a person. Evidence tables will be used to summarize the benefits and harms and the strengths and limitations of the body of evidence. The new evidence framework will enhance the ACIP's decision-making process by making it more transparent, consistent and systematic. Published by Elsevier Ltd.
引用
收藏
页码:9171 / 9176
页数:6
相关论文
共 35 条
[1]  
[Anonymous], METH REF GUID EFF CO
[2]  
[Anonymous], HLTH PEOPL
[3]  
Atkins D, 2004, BMJ-BRIT MED J, V328, P1490
[4]   Efficacy, immunogenicity, and safety of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine at the end of shelf life [J].
Block, Stan L. ;
Vesikari, Timo ;
Goveia, Michelle G. ;
Rivers, Stephen B. ;
Adeyi, Ben A. ;
Dallas, Michael J. ;
Bauder, Jeffrey ;
Boslego, John W. ;
Heaton, Penny M. .
PEDIATRICS, 2007, 119 (01) :11-18
[5]   Developing an evidence-based Guide to Community Preventive Services -: Methods [J].
Briss, PA ;
Zaza, S ;
Pappaioanou, M ;
Fielding, J ;
Wright-De Agüero, L ;
Truman, BI ;
Hopkins, DP ;
Mullen, PD ;
Thompson, RS ;
Woolf, SH ;
Carande-Kulis, VG ;
Anderson, L ;
Hinman, AR ;
McQueen, DV ;
Teutsch, SM ;
Harris, JR .
AMERICAN JOURNAL OF PREVENTIVE MEDICINE, 2000, 18 (01) :35-43
[6]   PERTINENCY OF AN EXTRANEOUS VARIABLE [J].
BROSS, IDJ .
JOURNAL OF CHRONIC DISEASES, 1967, 20 (07) :487-&
[7]   A global look at national Immunization Technical Advisory Groups [J].
Bryson, Maggie ;
Duclos, Philippe ;
Jolly, Ann ;
Cakmak, Niyazi .
VACCINE, 2010, 28 :A13-A17
[8]   A systematic review of national immunization policy making processes [J].
Bryson, Maggie ;
Duclos, Philippe ;
Jolly, Ann ;
Bryson, Jessica .
VACCINE, 2010, 28 :A6-A12
[9]  
CDC, CHART ADV COMM IMM P
[10]  
*CDCP, 2008, MMWR-MORBID MORTAL W, V57, P125